Nenad lisuride subcutaneous infusion regulatory update

Axxonis submitted an MAA to EMEA for Nenad lisuride subcutaneous infusion to treat advanced Parkinson's disease (PD). Lisuride, a dopamine agonist and serotonin (5- HT2B) receptor antagonist, was orig...